131741-08-7
Chemical Structure
Simendan
Synonym(s): (rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259
- CAS No.: 131741-08-7
- Formula:C14H12N6O
- Molecular Weight:280.28
IUPAC Name: N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)carbonohydrazonoyl dicyanide
InChIKey: WHXMKTBCFHIYNQ-UHFFFAOYSA-N
SMILES: N#C/C(C#N)=N/NC1=CC=C(C2=NNC(CC2C)=O)C=C1
Biological Activity: Simendan ((rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259) is a calcium-sensitizing positive inotropic vasodilator compound that enhances myocardial contractility through calcium-dependent binding to cardiac troponin C and selectively inhibits cardiac phosphodiesterase (Phosphodiesterase) III, while inducing coronary and peripheral vasodilation and anti-ischemic effects. Simendan can be used for research on congestive heart failure, acute heart failure, myocardial infarction, myocardial ischemia, and thrombotic diseases[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Simendan | Simendan ((rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259) is a calcium-sensitizing positive inotropic vasodilator compound that enhances myocardial contractility through calcium-dependent binding to cardiac troponin C and selectively inhibits cardiac phosphodiesterase (Phosphodiesterase) III, while inducing coronary and peripheral vasodilation and anti-ischemic effects. Simendan can be used for research on congestive heart failure, acute heart failure, myocardial infarction, myocardial ischemia, and thrombotic diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lilleberg J, et al. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Clinical pharmacology and therapeutics. 1994 Nov;56(5):554-63.
- [2]. Lilleberg JM, et al. Hemodynamic effects of the novel cardiotonic drug simendan: echocardiographic assessment in healthy volunteers. Cardiovascular drugs and therapy. 1994 Apr;8(2):263-9.
- [3]. Levijoki J, et al. Improved survival with simendan after experimental myocardial infarction in rats. European journal of pharmacology. 2001 May 11;419(2-3):243-8.
